Background BCG vaccination provides incomplete protection against tuberculosis in infants. A new vaccine, modifi ed Vaccinia Ankara virus expressing antigen 85A (MVA85A), was designed to enhance the protective effi cacy of BCG. We aimed to assess safety, immunogenicity, and effi cacy of MVA85A against tuberculosis and Mycobacterium tuberculosis infection in infants.
Introduction
Tuberculosis is a major global health problem, with an estimated 8·7 million cases and 1·4 million deaths in 2011. 1 The Stop TB Partnership developed the Global Plan to Stop TB: 2006 -2015 , with a goal of tuberculosis elimination by 2050. 2 One of the long-term strategies essential for control of the epidemic is eff ective vaccination. The existing BCG vaccine protects against disseminated tuberculosis in young children, 3, 4 but pro tection against pulmonary tuberculosis is very variable. [4] [5] [6] Effi cacy against infection with Mycobacterium tuberculosis has only been reported in observational studies in low-burden settings. 7 In endemic countries such as South Africa, the incidence of tuberculosis in infants and young children is very high despite high BCG coverage. 8, 9 An improved infant tuberculosis vaccination regimen is urgently needed.
12 candidate vaccines are being tested in clinical trials.
10
MVA85A is a recombinant strain of modifi ed Vaccinia Ankara virus expressing the immunodominant M tuberculosis protein, antigen 85A. 11 MVA85A has been developed as a heterologous boost for BCG. 11 Boosting BCG with MVA85A improved BCG-induced protection against mycobacterial challenge in animals. [12] [13] [14] [15] MVA85A was well tolerated in clinical trials in infants. 11, 16, 17 Furthermore, a BCG prime-MVA85A boost immunisation regimen in infants induced antigen-specifi c Th1 and Th17 cells, 16 which are regarded as important in protection against tuberculosis. We aimed to further assess safety of MVA85A in HIV-negative infants who were previously vaccinated with BCG. As secondary endpoints, we also aimed to assess effi cacy of MVA85A against tuberculosis and M tuber culosis infection beyond that of BCG alone, assess immunogenicity of MVA85A, and identify correlates of protection. To our knowledge, our investigation was the fi rst infant effi cacy trial of a new tuberculosis vaccine since BCG was last assessed in infants as part of the Chingleput-Madras trial that started in 1968. 20 
Methods

Study design and participants
We undertook a parallel-group, randomised, placebocontrolled, double-blind phase 2b trial at the South African Tuberculosis Vaccine Initiative (SATVI) site in a rural region near Cape Town, South Africa. The region has a population of about 290 000 people and an annual birth cohort of about 7000 babies. The overall incidence of tuberculosis in South Africa in 2011 was estimated to be almost 1% (993 per 100 000 individuals). 1 The incidence of tuberculosis in children younger than 2 years was about 3% at our trial site. 21 Parents of recently born infants were approached at local immunisation clinics or at home about study participation. We enrolled healthy infants, aged 4-6 months and who had received BCG (Danish 1331, Statens Serum Institut, Denmark) within 7 days of birth. Infants had to have received all age-appropriate routine immunisations, and two doses of pneumococcal conjugate vaccine at least 28 days before study vac cination (amended to 14 days during enrolment). All infants had to be HIV ELISA negative, QuantiFERON-TB Gold In-tube test (QFT; Cellestis, Australia) negative, and have had no substantial exposure to a patient with known tuberculosis. The appendix contains the study protocol.
The trial was approved by the University of Cape Town Faculty of Health Sciences Human Research Ethics Committee, Oxford University Tropical Research Ethics Committee, and the Medicines Control Council of South Africa. Parents or legal guardians provided written, informed consent.
Randomisation and masking
We randomly allocated infants in a 1:1 ratio, with a block size of four, by use of an interactive voice/online response system to receive one intradermal dose of MVA85A (1×10⁸ plaque-forming units in 0·06 mL) or an equal volume of Candida skin test antigen (Candin, AllerMed, USA) as placebo. Doses were prepared and labelled in masked syringes by an unmasked study pharma cist. An independent statistician prepared the randomisation schedule. The parents or legal guardians of study participants, study staff administering vac cinations or undertaking follow-up clinic assessments, and lab oratory staff were masked to intervention group assignment.
Procedures
The study design included specifi c cohorts for specialised analyses, but all participants were followed up for assessment of effi cacy and incidence of serious adverse events. Peripheral blood for routine haematological and biochemical tests was taken at screening and on day 7 and day 28 after vaccination in an initial safety cohort of at least 330 infants (study group 1). We assessed immunogenicity in three subsequent cohorts of up to 60 participants with an enzyme-linked immunosorbent spot analysis (study group 2), an intracellular cytokine staining (ICS) assay for peripheral blood mononuclear cell (PBMCs) counts (study group 3), and a whole blood ICS assay (study group 4). We enrolled remaining infants into a fi fth cohort (study group 5). PBMCs obtained from all infants before and after vaccination were cryopreserved for future correlates analyses. We did QFT testing at screening, day 336, at the end of study visit, and for infants admitted to a dedicated study ward for investigation for tuberculosis. 21 We obtained data for incidence of solicited and unsolicited local (injection site) and systemic adverse events reported by parents or guardians on diary cards for 7 days after vaccination and by direct questioning by study staff for 28 days after vaccination. We also obtained data for serious adverse events through out follow-up by active surveillance. Adverse events were assessed by the trial investigators and serious adverse events were assessed by the trial investigators and a local medical monitor, acting on behalf of the sponsor, to determine relation to vaccination. The trial investigators and local medical monitor were masked to intervention group throughout the trial. The safety monitoring committee (SMC) did not determine the association or severity of the adverse events. When the last infant in the safety cohort completed day 84, the SMC reviewed unmasked safety data to determine if a pattern of adverse events related to MVA85A or other safety concerns existed so as to advise on further enrolments. The SMC also conducted a second unmasked analysis-by-group safety and risk review after the 1000th infant completed their visit at study day 84.
We actively followed up infants every 3 months to identify any signs, symptoms, or exposure that merited further investigation. Participants who had a persistent cough, failure to thrive, weight loss crossing a major centile band, QFT or tuberculin skin test conversion, household tuberculosis contact, or any other condition causing investigator concern were admitted to the study ward. Standardised investigations involved assessments with chest radiography, tuberculin skin test, QFT, HIV-ELISA, two consecutive early morning gastric lavage samples, and two induced sputa. Gastric lavage and sputum samples underwent auramine smear microscopy, GeneXpert MTB/RIF (Cepheid, USA; routinely from January, 2011, onwards), and MGIT (Becton Dickinson, Sparks, USA) liquid culture and sensitivity See Online for appendix testing. Positive samples were speciated by PCR. We developed a hierarchy of three disease endpoint defi nitions. End point 1 (panel 1) and endpoint 2 (appendix p 49) were based on the presence of specifi c clinical, radiological, and microbiological fi ndings. 22 Endpoint 2 (which included all infants who met endpoint 1 criteria) had marginally less stringent criteria to defi ne tuberculosis infection and household exposure. End point 3 included all participants placed on treatment for tuberculosis by a health professional. This approach allowed objective case classifi cation without the need for an adjudication committee.
The endpoint of infection with M tuberculosis was defi ned as conversion to a positive QFT test at any time during follow-up. We assessed rates of QFT conversion 1 year after vaccination and at end of study in those participants not previously started on anti-tuberculous treatment.
We measured immunological sensitisation to M tuberculosis antigens, suggesting M tuberculosis infection, by QFT during screening, 1 year after vaccination, and at the close-out visit. We obtained blood samples from study groups 2-4 for immunogenicity analyses 7 days before vaccination and 7 days or 28 days after vaccination. We assessed immunogenicity with an ex-vivo interferon γ enzyme-linked immunosorbent spot assay, together with PBMC and whole blood ICS assays done as previously described. 23 Further details of the methods are available in the appendix.
Statistical analyses
The primary study outcome was safety in all vaccinated participants (safety population), including all solicited, unsolicited, and serious adverse events. We compared the proportion of participants with at least one such adverse event in the placebo and MVA85A groups with Fisher's exact test, and we calculated two-sided exact 95% CIs for proportions of individual events within treatment groups. We did immunogenicity analyses for all vaccinated participants enrolled in study groups 2-4. Statistical analyses were prespecifi ed in a statistical analysis plan, signed off prior to study database lock and unmasking of data (appendix).
The primary effi cacy outcome was incidence of endpoint 1 and the secondary effi cacy outcome was infection with M tuberculosis. Endpoints 2 and 3 were exploratory effi cacy outcomes. All effi cacy analyses were based on the per-protocol population, consisting of all randomly allocated participants who received at least one dose of study vaccine as randomised, and who had no major protocol deviations.
The primary statistical method for analysis of endpoint 1 was vaccine effi cacy, defi ned as 1 minus the estimated hazard ratio based on a Cox regression analysis of time to fi rst diagnosis of endpoint 1. The Cox model contained one indicator variable for treatment group. To investigate the potential eff ect of variable follow-up times, we also did this analysis with a predefi ned cutoff of 2 years after vaccination. Analysis of endpoint 1 also included time (months) to initial tuberculosis diagnosis from day of vaccination in each treatment group with the Kaplan-Meier estimate of the survival function by treatment group, and the exact binomial method to estimate vaccine effi cacy and its corresponding 95% CI (Clopper-Pearson with mid-p adjustment) conditional on the total number of events. We included participants with more than one diagnosis (eg, a diagnosis of tuberculosis endpoint 2 that was subsequently diagnosed as endpoint 1) in analyses separately for each diagnostic level. For the analysis of secondary and exploratory effi cacy endpoints, no adjustment for multiplicity was done. We regarded a twosided p value of less than 0·05 as signifi cant. Sum maries were presented for all cases reported during the study, and also, all cases with a diagnosis during the fi rst 2 years of individual follow-up.
For effi cacy analyses, we based the sample size calculation on the primary effi cacy endpoint of tuberculosis (endpoint 1). We assumed a cumulative tuberculosis incidence of 3% after a median of 18 months' follow-up • Evidence of mycobacterial infection defi ned as two acid-fast positive smears (each from a separate collection) that were morphologically consistent with mycobacteria from either sputum or gastric aspirate that were not found to be non-tuberculous mycobacteria bacteria on culture; QuantiFERON-TB Gold In-tube test conversion from negative to positive; or tuberculin skin test ≥15 mm and • Radiographic fi ndings compatible with tuberculosis defi ned as ≥1 of the following factors identifi ed independently by at least two of three paediatric radiologists serving on a masked review panel: calcifi ed Ghon focus, pulmonary cavity, hilar or mediastinal adenopathy, pleural eff usion, or airspace opacifi cation and • Clinical manifestations compatible with tuberculosis defi ned as cough without improvement for >2 weeks; weight loss of >10% of bodyweight for >2 months; or failure to thrive, defi ned as crossing >1 complete major centile band (<97th-90th, <90th-75th, <75th-50th, <50th-25th, <25th-10th, and <10th-3rd weight-for-age centiles) downward for >2 months in the placebo group, 21 with an estimated 7·5% loss to follow-up. 24 Thus, 1392 participants per intervention group would provide a 90% chance of detection of a 60% reduction between the intervention and control groups based on a two-sided log-rank test at a signifi cance level of 0·05. We implemented a 6 month exten sion to the planned follow-up to achieve the target case accrual.
For safety analyses, the sample size of 1392 participants receiving MVA85A would provide a greater than 75% chance of observing an adverse event that had an approximately one in 1000 actual rate of occurrence. 
Role of the funding source
Aeras was the trial sponsor. Aeras and the OxfordEmergent Tuberculosis Consortium (OETC) contributed to study design, data interpretation, and writing of the manuscript. MDT, MH, BSL, TJS, MAS, SL, HM, and HMcS had complete access to the data. HMcS had fi nal responsibility for the decision to submit for publication.
Results
Between
22 363 infants were entered into study group 1 (initial safety cohort; 182 in MVA85A group and 181 in the placebo group); 54 into group 2 (27 and 27), 54 into group 3 (27 and 27), and 39 into group 4 (19 and 20; immunogenicity groups); and 2287 in group 5 (1144 and 1143; correlates of protection). Follow-up was completed in October, 2012. The perprotocol population was 2794, excluding three participants from the intention-to-treat population (fi gure 1). The intention-to-treat analysis is not reported.
Demographic and baseline clinical characteristics of the study participants were much the same between groups (table 1). In the per-protocol population, median followup for 1399 recipients of MVA85A was 24·6 months (range 0·2-37·3; IQR 19·2-27·8) and for 1395 controls was 24·6 months (0·3-37·3; 19·2-30·1). The number of participants dis con tinuing the study did not diff er between the two treatment groups (fi gure 1). 126 infants (5%) were lost to follow-up, 11 died (<1%), and 62 (2%) had consent withdrawn.
At least one local adverse event was reported in 628 (45%) of 1396 controls who received the allocated intervention and 1251 (89%) of 1399 recipients of MVA85A. At least one systemic adverse event was reported in 1059 (76%) controls and 1120 (80%) of recipients of MVA85A. At least one serious adverse event was reported in 258 (18%) controls and 257 (18%) recipients of MVA85A (appendix). No serious adverse events related to vaccine were reported in the MVA85A group, but one serious adverse event regarded as related to placebo occurred in the placebo group (short admission to hospital for fever 4 days after vaccination). 417 (64%) of 648 serious adverse events were acute lower-respiratory-tract infections or gastro enteritis (appendix). Seven (1%) infants died in the vaccine group (two from kwashiorkor, two from nontuberculous meningitis, one from gastroenteritis, one from asphyxia due to drowning, and one from sudden death) and four (<1%) infants died in the placebo group (two from gastro enteritis, one from encephalitis, and one from a lower-respiratory-tract infection). During follow-up, 510 (37%) of 1395 recipients of placebo and 507 (36%) of 1399 recipients of MVA85A were admitted to the study ward for investigation. MVA85A induced an Ag85-specifi c T-cell response as measured by ex-vivo interferon γ enzyme-linked im munosorbent spot (median 136 spot-forming cells per million PBMCs, IQR 87-362; fi gure 2). Whole blood ICS showed that these cells were CD4-positive T cells predominantly expressing interferon γ, TNFα, and interleukin 2 (fi gure 2). We also detected CD4-positive interleukin 17-positive T cells (fi gure 2), some of which co-expressed Th1 cytokines (data not shown). These responses were not detected in recipients of placebo. No CD8-positive T-cell responses were detectable and no responses were detected with ICS completed on cryo preserved PBMCs (data not shown). Table 2 shows vaccine effi cacy and numbers of infants who met endpoints 1, 2, or 3 by intervention group. For analysis with follow-up data truncated at 2 years after vaccination, vaccine effi cacy was 23·9% (95% CI -27·9 to 54·7) for endpoint 1, -0·7% (-52·3 to 33·4) for end point 2, and -3·6% (-29·0 to 16·8) for endpoint 3. A post-hoc review of case distribution in the fi rst year showed 16 recipients of placebo met endpoint 1 as did ten MVA85A recipients. Figure 3 shows infected with M tuberculosis as defi ned by QFT conversion during the course of the study. Vaccine effi cacy against infection was -3·8% (95% CI -28·1 to 15·9). Effi cacy was much the same when the comparison was restricted to QFT conversion at day 336 and end of study visit (data not shown).
Discussion
We report completion of a phase 2b safety and effi cacy trial for infants with a new tuberculosis vaccine strategy (panel 2). In this trial, MVA85A was well tolerated and immunogenic in healthy infants who had previously been vaccinated with BCG, with a safety and immunogenicity profi le consistent with that reported in other studies of infants. 16, 17 However, we noted no signifi cant effi cacy against tuberculosis or M tuberculosis infection.
This absence of effi cacy was not consistent with fi nd ings from studies in animals, which suggested poten tial for effi cacy, [12] [13] [14] [15] and evidence of immunogenicity in previous clinical trials 16, 17, 23 that measured immune responses regarded as important for protection. 18, 19 Our results suggest that the CD4-positive T cells induced by MVA85A-at least at the modest frequencies noted in this trial-do not correlate with protection against tuberculosis or M tuberculosis infection. Fre quencies of antigen-specifi c Th1 cells observed in infants with MVA85A were up to a tenth of the frequencies noted in adults. 16, 25 Our effi cacy trial was undertaken in infants. However, this group is not responsible for most transmission of M tuberculosis. Thus, MVA85A could potentially protect adolescents or adults against pulmonary tuberculosis, in view of the fact that immunologically immature infants do not respond as well to this vaccine as adults do. MVA85A could also potentially have high effi cacy in people of all ages against severe forms of tuberculosis, including pulmonary tuberculosis, without preventing infection or mild forms of disease. A high effi cacy against severe disease could be masked in a trial that pre dominantly detects mild forms of tuberculosis. The sample size of a trial powered to detect only severe or disseminated disease would be prohibitively large. The safety and immunogenicity of MVA85A alone in infants exposed to HIV is currently being assessed. 26 BCG-specifi c Th1 and Th17 responses were recently shown not to correlate with risk of tuberculosis in infants after BCG vac cination. 27 Whether a substantially greater magnitude of response, a response that is qual itatively diff erent, or a completely new immunological response would be necessary for protection is unclear. In our study, frequencies of BCGprimed Ag85A-specifi c T cells detected before MVA85A vaccination were very low or undetectable (fi gure 2). Conversely, adults and adoles cents have signifi cantly higher Ag85A-specifi c responses before vaccination, 16 which might be an important factor in the stronger responses induced by MVA85A in older individuals. MVA85A was designed to boost BCG-primed responses, and the low frequencies of BCG-induced cells in infants might restrict the immunogenicity, and poten tially the effi cacy, of MVA85A in this age group. Ongoing assessment of study samples for potential correlates of risk might also yield important insights into why MVA85A did not confer protection in this trial and could add to the design and assessment of the next generation of tuberculosis vaccine candidates. Identifi cation of immune correlates of protection would greatly aid vaccine design and assessment. However such correlates can only be identifi ed in trials in which effi cacy was shown. Identification and optimisation of animal models that accurately predict effi cacy in human beings is also needed. Other effi cacy trials of new HIV and malaria vaccines have reported early but waning effi cacy. 28, 29 In this trial, a posthoc analysis of distribution of case accrual in the fi rst year suggested a possible early eff ect on disease that merits further study of route of adminis tration, regimen, and dosing strategies with MVA85A and other vaccines.
Despite concerns about potential immunopathology induced by new tuberculosis vaccines, 30 we noted no evidence for this eff ect. The high incidence of respiratory and gastrointestinal serious adverse events recorded in this trial refl ects the known burden of childhood morbidity in this community. 24 High numbers of unrelated serious adverse events should be expected in clinical trials in infant populations in developing countries. The high frequency of mild, self-limiting local reactions in MVA85A recipients is consistent with previous studies. 16, 17 These local reactions were only partially controlled for by Candin, a placebo selected for its local reactogenicity profi le. The overall safety profi le supports modifi ed Vaccinia Ankara virus as a suitable vector for infant vaccination strategies.
The high incidence of disease noted in our study was comparable to the high rates noted in previous trials. 21, 24 We noted no confi rmed cases of disseminated tuber culosis (two cases of tuberculous meningitis met the defi nition for endpoint 2) and no deaths from tuber culosis, supporting our previous observation that disseminated and severe
Panel 2: Research in context
Systematic review To our knowledge, our trial is the fi rst effi cacy study of a novel BCG booster tuberculosis vaccine in infants. A systematic review is not applicable.
Interpretation
The safety of MVA85A reported in our large cohort is an important fi nding for tuberculosis vaccine development. However the absence of effi cacy noted, despite studies in animals suggesting potential for effi cacy and evidence of immunogenicity in previous clinical trials, was unexpected and suggests that the present parameters for selection of tuberculosis vaccine candidates might be inadequate. The relatively weak immunogenicity we noted in this study makes it diffi cult to conclude whether a higher magnitude response (ie, one that is qualitatively diff erent or a completely new immunological mechanism) will be required for a protective vaccine. Lessons learnt from this trial, including trial design, execution, and vaccine selection, will be of enormous importance to the broader specialty of vaccine development.
tuberculosis are uncommon in a setting of modern trials with active surveillance, eff ective isoniazid prophylaxis, and eff ective anti-tuber culous treatment. 21 The high overall rate of M tuberculosis infection noted in this trial (349 [13%] of 2792) suggests a high level of exposure and trans mission in this com munity. This infection burden sug gests that M tuberculosis infection might be a suitable endpoint for future trials of new tuberculosis vaccines that aim to prevent infection and subsequent disease. Because BCG is regarded as less eff ective for prevention of infection than prevention of disease, our fi nding that MVA85A did not prevent infection is unsurprising and should be interpreted separately from the fi ndings about effi cacy against disease. We recognise that QFT has not been validated as a diagnostic test for M tuberculosis infection in infants and young children; however, a previous study 31 done by our group showed good corre lation between QFT and the tuberculin skin test.
Our study showed that a large effi cacy trial of a new tuberculosis vaccine in a high-burden setting is feasible with a stringent and objective case defi nition that incorporated the primary elements proposed in a recent consensus statement. 32 We have also shown that standardised investigation for tuberculosis with multiple respiratory sampling, microbiological confi rmation of disease, and masked expert panel review of digital radiograph images is feasible in a developing country setting where tuberculosis vaccine effi cacy trials are likely to be done. We recognise that there is no gold standard defi nition of childhood tuberculosis, 33 but we believe that the hierarchal endpoint defi nition used in this trial is robust and might be suitable for future tuberculosis vaccine trials.
Cohort retention was very high in this trial, and no evidence was noted that the rate of loss to follow-up had a diff erential eff ect on case accrual. Similarly, exclusion of three enrolled infants in the per-protocol analysis did not aff ect the results.
In conclusion, MVA85A was well tolerated, modestly immunogenic but unable to confer signifi cant protection against tuberculosis or M tuberculosis infection. The infor mation gained from the successful execution of this study will aid the planning of future trials and vaccination strategies. Substantial global eff orts to develop an improved vaccine against tuberculosis must continue.
